288 related articles for article (PubMed ID: 28089936)
1. Biodegradable lipid nanoparticles induce a prolonged RNA interference-mediated protein knockdown and show rapid hepatic clearance in mice and nonhuman primates.
Suzuki Y; Hyodo K; Suzuki T; Tanaka Y; Kikuchi H; Ishihara H
Int J Pharm; 2017 Mar; 519(1-2):34-43. PubMed ID: 28089936
[TBL] [Abstract][Full Text] [Related]
2. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo.
Jayaraman M; Ansell SM; Mui BL; Tam YK; Chen J; Du X; Butler D; Eltepu L; Matsuda S; Narayanannair JK; Rajeev KG; Hafez IM; Akinc A; Maier MA; Tracy MA; Cullis PR; Madden TD; Manoharan M; Hope MJ
Angew Chem Int Ed Engl; 2012 Aug; 51(34):8529-33. PubMed ID: 22782619
[TBL] [Abstract][Full Text] [Related]
3. Enhanced Delivery of siRNA to Retinal Ganglion Cells by Intravitreal Lipid Nanoparticles of Positive Charge.
Huang X; Chau Y
Mol Pharm; 2021 Jan; 18(1):377-385. PubMed ID: 33295773
[TBL] [Abstract][Full Text] [Related]
4. siRNA-lipid nanoparticles with long-term storage stability facilitate potent gene-silencing in vivo.
Suzuki Y; Hyodo K; Tanaka Y; Ishihara H
J Control Release; 2015 Dec; 220(Pt A):44-50. PubMed ID: 26478014
[TBL] [Abstract][Full Text] [Related]
5. Engineering of small interfering RNA-loaded lipidoid-poly(DL-lactic-co-glycolic acid) hybrid nanoparticles for highly efficient and safe gene silencing: A quality by design-based approach.
Thanki K; Zeng X; Justesen S; Tejlmann S; Falkenberg E; Van Driessche E; Mørck Nielsen H; Franzyk H; Foged C
Eur J Pharm Biopharm; 2017 Nov; 120():22-33. PubMed ID: 28756280
[TBL] [Abstract][Full Text] [Related]
6. Quantitation of physiological and biochemical barriers to siRNA liver delivery via lipid nanoparticle platform.
Xu Y; Ou M; Keough E; Roberts J; Koeplinger K; Lyman M; Fauty S; Carlini E; Stern M; Zhang R; Yeh S; Mahan E; Wang Y; Slaughter D; Gindy M; Raab C; Thompson C; Hochman J
Mol Pharm; 2014 May; 11(5):1424-34. PubMed ID: 24588618
[TBL] [Abstract][Full Text] [Related]
7. Alterations in the hepatic transcriptional landscape after RNAi mediated ApoB silencing in cynomolgus monkeys.
Hamza MS; Kumar C; Chia SM; Anandalakshmi V; Boo N; Strapps W; Robinson M; Caguyong M; Bartz S; Tadin-Strapps M; van Gool A; Shih SJ
Atherosclerosis; 2015 Oct; 242(2):383-95. PubMed ID: 26275376
[TBL] [Abstract][Full Text] [Related]
8. Structure, activity and uptake mechanism of siRNA-lipid nanoparticles with an asymmetric ionizable lipid.
Suzuki Y; Ishihara H
Int J Pharm; 2016 Aug; 510(1):350-8. PubMed ID: 27374199
[TBL] [Abstract][Full Text] [Related]
9. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
10. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
[TBL] [Abstract][Full Text] [Related]
11. PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse Liver.
Demers A; Samami S; Lauzier B; Des Rosiers C; Ngo Sock ET; Ong H; Mayer G
Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2517-25. PubMed ID: 26494228
[TBL] [Abstract][Full Text] [Related]
12. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
Sasaki M; Terao Y; Ayaori M; Uto-Kondo H; Iizuka M; Yogo M; Hagisawa K; Takiguchi S; Yakushiji E; Nakaya K; Ogura M; Komatsu T; Ikewaki K
Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1171-8. PubMed ID: 24675665
[TBL] [Abstract][Full Text] [Related]
13. Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA.
Chen S; Tam YYC; Lin PJC; Sung MMH; Tam YK; Cullis PR
J Control Release; 2016 Aug; 235():236-244. PubMed ID: 27238441
[TBL] [Abstract][Full Text] [Related]
14. siRNA-mediated inhibition of SREBP cleavage-activating protein reduces dyslipidemia in spontaneously dysmetabolic rhesus monkeys.
Murphy BA; Tadin-Strapps M; Jensen K; Mogg R; Liaw A; Herath K; Bhat G; McLaren DG; Previs SF; Pinto S
Metabolism; 2017 Jun; 71():202-212. PubMed ID: 28521874
[TBL] [Abstract][Full Text] [Related]
15. Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells.
Basha G; Novobrantseva TI; Rosin N; Tam YY; Hafez IM; Wong MK; Sugo T; Ruda VM; Qin J; Klebanov B; Ciufolini M; Akinc A; Tam YK; Hope MJ; Cullis PR
Mol Ther; 2011 Dec; 19(12):2186-200. PubMed ID: 21971424
[TBL] [Abstract][Full Text] [Related]
16. Engineering a biomimetic system for hepatocyte-specific RNAi treatment of non-alcoholic fatty liver disease.
He X; Chang Z; Chen F; Zhang W; Sun M; Shi T; Liu J; Chen P; Zhang K; Guan S; Zhao Z; Li M; Dong WF; Shao D; Yang C
Acta Biomater; 2024 Jan; 174():281-296. PubMed ID: 37951519
[TBL] [Abstract][Full Text] [Related]
17. Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.
Tavori H; Giunzioni I; Predazzi IM; Plubell D; Shivinsky A; Miles J; Devay RM; Liang H; Rashid S; Linton MF; Fazio S
Cardiovasc Res; 2016 May; 110(2):268-78. PubMed ID: 26980204
[TBL] [Abstract][Full Text] [Related]
18. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
[TBL] [Abstract][Full Text] [Related]
19. Multifunctional pH-Sensitive Amino Lipids for siRNA Delivery.
Gujrati M; Vaidya A; Lu ZR
Bioconjug Chem; 2016 Jan; 27(1):19-35. PubMed ID: 26629982
[TBL] [Abstract][Full Text] [Related]
20. Understanding structure-activity relationships of pH-sensitive cationic lipids facilitates the rational identification of promising lipid nanoparticles for delivering siRNAs in vivo.
Sato Y; Hashiba K; Sasaki K; Maeki M; Tokeshi M; Harashima H
J Control Release; 2019 Feb; 295():140-152. PubMed ID: 30610950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
